アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) (internal sequence)
Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487.
This product is a recombinant rabbit monoclonal antibody.
Our Abpromise guarantee covers the use of ab109538 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 118 kDa.|
|ICC||1/50 - 1/100.|
|Flow Cyt||Use at an assay dependent concentration.|
Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling Insulin degrading enzyme / IDE with purified ab109538 at 1/150 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti-rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: IDE knockout HAP1 cell lysate (20 µg)
Lane 3: K562 cell lysate (20 µg)
Lane 4: HepG2 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab109538 observed at 118 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab109538 was shown to specifically react with IDE when IDE knockout samples were used. Wild-type and IDE knockout samples were subjected to SDS-PAGE. ab109538 and ab8245 (loading control to GAPDH) were both diluted 1/2000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 h at room temperature before imaging.
ab109538 has not yet been referenced specifically in any publications.